Get notified of page updates
Education > XRAY > Search Results

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search by Topic Submit an Article for Review

All XRAYs

31 through 40 of 308

Relevance: Medium

Strength of Science: Medium-High

Research Timeline: Human Research

View Related Clinical Trials

Study : Early removal of ovaries may be linked to small increase in risk of Parkinson’s disease in later life

Most relevant for: Women considering risk-reducing removal of both ovaries

The lifetime risk of developing Parkinson’s disease is low. However, having surgery to remove both ovaries before natural menopause can slightly increase the risk of Parkinson's disease later in life. Researchers studied over 20 years of medical records, which confirmed this small increase in risk, particularly for women who have their ovaries removed before age 43. (Posted 5/3/23)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium

Research Timeline: Human Research

View Related Clinical Trials

Study : Hormonal birth control may reduce ovarian cancer risk in people with BRCA mutations

Most relevant for: Women with BRCA1 or BRCA2 mutations who are interested in reducing their ovarian cancer risk

Hormonal birth control pill is linked to reduced ovarian cancer among people with an inherited BRCA mutation. Longer-acting forms of birth control given by implant, injection or as an intrauterine device may be associated with lower ovarian cancer risk for people with an inherited BRCA mutation. (Posted 4/28/23)

Este artículo está disponible en español.

Read More

Relevance: Medium

Strength of Science: Medium-High

Research Timeline: Human Research

Study : Hair straightening products linked to small increased risk of endometrial cancer

Most relevant for: People who use hair straightening products

Many people use products to straighten their hair. Use of these products, especially frequent use, is linked to a small increase in endometrial cancer.  (Posted 4/18/23)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Breast cancer outcomes improved with CDK4/6 inhibitor treatment

Most relevant for: People with HR-positive HER2-negative advanced breast cancer

A study showed that people with metastatic breast cancer who took an oral drug known as a CDK4/6 inhibitor combined with hormone therapy did better than people who took hormone therapy alone. The drug combination improved the length of time before cancer worsened or returned. After six years of treatment, people who took this drug combination lived longer compared to those who took hormone therapy alone. (Posted 4/5/23)

Este artículo está disponible en español.

Read More

Relevance: Medium

Strength of Science: Medium

Research Timeline: Animal Studies

View Related Clinical Trials

Study : Weight may affect breast cancer risk in women with an inherited BRCA mutation

Most relevant for: People with an inherited mutation in BRCA1 or BRCA2 concerned about their breast cancer risk

A study that looked at normal breast cells from women with an inherited BRCA mutation found more DNA damage among women who were overweight (based on a measurement known as body mass index) than those who were not overweight. The results suggest that maintaining a lower weight may reduce breast cancer among this high-risk population. (Posted 3/30/23)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : New oral drug treatment for some advanced breast cancer

Most relevant for: People with HR-positive, HER2-negative advanced breast cancer

The FDA has approved a new oral drug called Oserdu for the treatment of HR-positive, HER2-negative advanced breast cancer. A blood test was also approved to help doctors identify patients who would benefit most from this new treatment. (Posted 3/20/23)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Study : Systemic racism may delay breast biopsy for Black and Asian people

Most relevant for: People who have had an abnormal mammogram

Black and Asian people are more likely to have to wait more than 90 days between an abnormal mammogram and a biopsy compared to white people. After accounting for other factors, the authors conclude that these disparities may be due to systemic racism. (Posted 3/8/23)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: High

Research Timeline: Human Research

View Related Clinical Trials

Study : Promising early results for treating metastatic prostate cancer

Most relevant for: People with metastatic castration-resistant prostate cancer (mCRPC)

The TALAPRO studies looked at how well the oral drug Talzenna (talazoparib) works as a treatment for metastatic castration-resistant prostate cancer (mCRPC). The addition of Talzenna to treatment with Xtandi (enzalutamide) increased the time until the cancer got worse or came back (progression-free survival). The greatest benefit was seen in people who had an inherited or tumor mutation in a gene that repairs DNA damage (such as ATM, BRCA1, BRCA2 and others). (Posted 3/1/23)

Update: On June 20, 2023, the Food and Drug Administration (FDA) approved the combination of Talzenna with Xtandi as an initial treatment for some people with mCRPC for people with inherited or tumor mutations in genes that repair DNA damage. 

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: High

Study : Treatment to reduce bone fractures also improves breast cancer survival in postmenopausal people

Most relevant for: People with early-stage breast cancer who are post-menopausal

A large study looked at the effects of adding the bone-protective drug denosumab (Prolia), to standard hormone therapy for the treatment of early-stage, postmenopausal, HR-positive breast cancer. The researchers found that adding denosumab to aromatase inhibitor hormonal therapy improved bone health, disease-free survival and overall survival. (Posted 2/27/23)

Este artículo está disponible en español.

Read More

Relevance: Medium

Strength of Science: Medium-High

View Related Clinical Trials

Study : Increasing soy in your diet may lower your cancer risk

Most relevant for: People interested in reducing cancer risk

This study looked at a link between a diet rich in soy and cancer risk. With the addition of more recent literature, this study suggests that soy lowers the risk of cancer in the general population. (Posted 2/24/23)

Este artículo está disponible en español.

Read More